BSE · 524723
Arvaya Healthcare Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-1 Cr — a -890% net margin, versus 8.6% the period before.
Shareholding
As of 2026-10-31
- Promoter28.33%
- Public71.67%
3,529 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.04× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 2.28 percentage points to 28.33% in the latest disclosure.
- Reported zero revenue in 5 of the last 8 disclosed periods.
Peer comparison
Trading · ranked #80 of 693 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,63,802 Cr | 101.43 | 3.71 | 3.66% | 4.59% |
| Avenue Supermarts Limited | ₹2,24,349 Cr | 71.98 | 8.6 | 11.94% | 4.2% |
| Trent Ltd. | ₹1,68,779 Cr | 88.12 | 21.69 | 24.4% | 8.62% |
| FSN E-Commerce Ventures Ltd. | ₹1,04,618 Cr | 314.83 | 63.16 | 19.49% | 2.85% |
| Aditya Infotech Limited | ₹50,886 Cr | 82.37 | 13.87 | 16.16% | 10.38% |
| Vishal Mega Mart Limited | ₹45,148 Cr | 50.19 | 5.7 | 11.37% | 6.45% |
| Aegis Logistics Limited | ₹42,976 Cr | 32.26 | 6.45 | 20.01% | 14.99% |
| Premier Energies Limited | ₹40,670 Cr | 22.98 | 7.88 | 34.23% | 19.11% |
| Redington Limited | ₹27,339 Cr | 13.62 | 2.54 | 18.62% | 1.31% |
| Honasa Consumer Limited | ₹16,378 Cr | 57.17 | 11.02 | 19.03% | 10.3% |
| Arvaya Healthcare Ltd.(this company) | ₹523 Cr | 573.68 | 8.74 | -2.06% | 3.59% |
AI analysis
AI-generated · google/gemini-2.5-flashArvaya Healthcare Ltd. (BIJOYHANSLTD) has a market capitalization of Rs 551 Cr. The company reported revenue of Rs 0.47 Cr and a profit margin of 0%. Its book value stands at Rs 12.08. The 52-week high for the share price was Rs 114.71, and the 52-week low was Rs 24.15.
Positives
- +The debt-to-equity ratio is low at 0.01.
- +Promoter holding remains consistent with no reported pledges.
Negatives
- −The company has reported negative return on equity (-206.4%) and return on capital employed (-1.9752%).
- −Current quarter revenue for Mar 2026 is reported as Rs 0 Cr, indicating no operational revenue.
- −The profit margin is 0%, indicating no profitability from operations.
- −The company is under ESM Stage 1 surveillance, which signifies increased regulatory scrutiny.
Financial performance
The company's revenue in Mar 2025 was Rs 0.4687403 Cr, following a revenue of Rs 0.5834072 Cr in Mar 2024. Net profit was Rs 0.1361204 Cr in Mar 2025, an improvement from a net loss of Rs -0.1172183 Cr in Mar 2024. Annual revenue experienced a decline from Rs 0.6147234 Cr in Mar 2021 to Rs 0.4687403 Cr in Mar 2025.
Profitability & returns
Arvaya Healthcare Ltd. currently reports a return on equity (ROE) of -206.4% and a return on capital employed (ROCE) of -1.9752%. The earnings per share (EPS) for the last reported period was Rs 0.45 in Mar 2025. The company's profit margin is 0% currently.
Balance sheet
The company's debt-to-equity ratio is 0.01, indicating low leverage. The book value per share is Rs 12.08. No dividend yield is reported.
Ownership & pledges
There are no reported promoter pledges. The number of shareholders is 3393.
Regulatory & surveillance
The company is currently under ESM (Enhanced Surveillance Measure) Stage 1, with measures including ESM. This indicates increased monitoring from regulatory bodies.
Data as of — price: 2026-11-14 · financials: Jun 26 · shareholding: Oct 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.